On Tuesday, Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) opened higher 2.71% from the last session, before settling in for the closing price of $477.52. Price fluctuations for VRTX have ranged from $377.85 to $519.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 22.39%. Company’s average yearly earnings per share was noted 4164.00% at the time writing. With a float of $256.31 million, this company’s outstanding shares have now reached $256.94 million.
The extent of productivity of a business whose workforce counts for 6100 workers is very important to gauge. In terms of profitability, gross margin is 86.09%, operating margin of -2.24%, and the pretax margin is 2.26%.
Vertex Pharmaceuticals, Inc (VRTX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Vertex Pharmaceuticals, Inc is 0.30%, while institutional ownership is 92.86%. The most recent insider transaction that took place on Mar 13 ’25, was worth 1,647,810. In this transaction EVP, Chief Scientific Officer of this company sold 3,231 shares at a rate of $510.00, taking the stock ownership to the 23,281 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Officer proposed sale 3,231 for $510.00, making the entire transaction worth $1,647,810.
Vertex Pharmaceuticals, Inc (VRTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 4164.00% per share during the next fiscal year.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Check out the current performance indicators for Vertex Pharmaceuticals, Inc (VRTX). In the past quarter, the stock posted a quick ratio of 2.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.20, a number that is poised to hit 4.24 in the next quarter and is forecasted to reach 20.81 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
The latest stats from [Vertex Pharmaceuticals, Inc, VRTX] show that its last 5-days average volume of 1.19 million was inferior to 1.53 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 67.72%. Additionally, its Average True Range was 15.98.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 79.40%, which indicates a significant increase from 78.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.58% in the past 14 days, which was lower than the 31.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $486.57, while its 200-day Moving Average is $471.05. Now, the first resistance to watch is $494.66. This is followed by the second major resistance level at $498.85. The third major resistance level sits at $505.90. If the price goes on to break the first support level at $483.42, it is likely to go to the next support level at $476.37. The third support level lies at $472.18 if the price breaches the second support level.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
There are currently 256,790K shares outstanding in the company with a market cap of 126.09 billion. Presently, the company’s annual sales total 11,020 M according to its annual income of -535,600 K. Last quarter, the company’s sales amounted to 2,912 M and its income totaled 913,000 K.
